Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer.
Akinori SasakiAkihito KawazoeTestuya EtoMashiro OkunakaSaori MishimaKentaro SawadaYoshiaki NakamuraDaisuke KotaniYasutoshi KubokiHiroya TaniguchiTakashi KojimaToshihiko DoiTakayuki YoshinoTetsuo AkimotoKohei ShitaraPublished in: ESMO open (2021)
Prior anti-PD-1 therapy might increase tumour response to taxanes plus ramucirumab without unexpected adverse events, which warrants further investigations in a large cohort.